Illustration: Eniola Odetunde/Axios

Drug pricing regulations would not decimate the pharmaceutical industry, according to an analysis from health policy researchers at West Health and Johns Hopkins.

Why it matters: This throws some cold water on Big Pharma's claims that new drug research and investments would evaporate if the federal government limits what they can charge for medications — the proposal du jour in Congress and the White House.

Details: The report from West Health, a policy group only funded by telecom moguls Mary and Gary West, found that drug companies have the highest profits of any industry when calculated as a "return on invested capital." And those profits would still be among the top if drug sales were reduced through federal negotiations or price caps.

  • "Pharma will still have this high rate of profitability, but it's also less volatile than other industries," said Sean Dickson, a health policy director at West Health and co-author of the report. "The demand for drugs is inelastic — people need to take them to stay alive."

Yes, but: Some economists and analysts criticized the report's methods — for example, focusing on publicly traded drug companies while leaving out smaller, failed drug firms could skew profitability. And while pension funds and institutional investors would not abandon pharma, the industry likely would change how and where to spend research dollars.

  • The Congressional Budget Office estimated Rep. Nancy Pelosi's bill would prevent eight to 15 new drugs from coming to market in the next decade.
  • However, CBO didn't say whether that reduction involved important drugs, or less valuable drugs (like "me-too" medications).

PhRMA, the industry's primary lobbying group, said the authors are "naive" to claim drug pricing regulations "would not have a devastating impact on research and development," and that "excluding smaller biotech companies from the analysis demonstrates a rudimentary understanding of the drug development process."

  • "Pharmaceutical companies will still need to invest in new drugs in order to earn revenue — it's their entire business model," Dickson said in response. "They could maintain their current research investments and still be enormously profitable."

The bottom line: Our reporting similarly shows that pharmaceutical companies easily hold the highest profits and margins in health care alone. It makes sense, considering these companies are granted patent monopolies for their products.

  • Changing the way drug prices are set does not mean profits, or research, would cease to exist. The debate is over the magnitude of pharmaceutical profits, and what would happen if those levels are reduced.

Go deeper

Biden confidants see VP choices narrowing to Harris and Rice

Photos: Tom Williams/CQ-Roll Call, Inc via Getty Images; Win McNamee/Getty Images

Confidants of Joe Biden believe his choices for vice president have narrowed to Sen. Kamala Harris and Susan Rice — and would be surprised if he picks anyone else.

The state of play: This is a snapshot of the nearly unanimous read that we get from more than a dozen people close to him.

An election like no other

Illustration: Eniola Odetunde/Axios

The coronavirus will make the 2020 presidential election different from any in modern history: Voting that begins earlier, results that take longer, mail carriers as virtual poll workers and October Surprises that pop in September.

The big picture: Perhaps 80 million Americans will vote early, by mail or in person, Tom Bonier, CEO of TargetSmart, a Democratic political data firm, tells Axios. That's going to set up more of an Election Season than an Election Day — and increase the odds of national turmoil over the vote count.

Exclusive: Inside McCarthy's new GOP messaging platform

House GOP Leader Kevin McCarthy (R-Calif.). Photo: Tasos Katopodis/Getty Images

House Republican Leader Kevin McCarthy (R-Calif.) has given his GOP colleagues new marching orders for stump speeches between now and November, as incumbents worry about how President Trump's own challenges may strain their re-election bids.

Driving the news: McCarthy delivered a PowerPoint presentation to the GOP conference in person last Thursday at the Capitol Visitor Center, with several members joining via Zoom, lawmakers and aides familiar with the gathering tell Axios.